Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CAO James George Chopas Sells 1,096 Shares of Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CAO James George Chopas sold 1,096 shares of the firm’s stock in a transaction dated Wednesday, January 22nd. The shares were sold at an average price of $30.43, for a total value of $33,351.28. Following the transaction, the chief accounting officer now directly owns 48,138 shares in the company, valued at $1,464,839.34. This trade represents a 2.23 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

James George Chopas also recently made the following trade(s):

• On Friday, January 17th, James George Chopas sold 715 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $29.96, for a total value of $21,421.40.
• On Monday, January 13th, James George Chopas sold 783 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $28.70, for a total value of $22,472.10.

Apellis Pharmaceuticals Trading Up 1.2 %

Shares of NASDAQ APLS opened at $30.76 on Friday. The stock has a market cap of $3.83 billion, a P/E ratio of -15.15 and a beta of 0.94. The company has a debt-to-equity ratio of 1.91, a current ratio of 4.36 and a quick ratio of 3.73. Apellis Pharmaceuticals, Inc. has a 1 year low of $24.34 and a 1 year high of $71.90. The firm has a 50-day moving average of $31.95 and a 200 day moving average of $33.25.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.14). Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The company had revenue of $196.83 million during the quarter, compared to the consensus estimate of $200.00 million. During the same period in the prior year, the firm earned ($1.17) earnings per share. The business’s revenue for the quarter was up 78.3% compared to the same quarter last year. As a group, sell-side analysts expect that Apellis Pharmaceuticals, Inc. will post -1.71 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. HC Wainwright restated a “buy” rating and issued a $57.00 target price on shares of Apellis Pharmaceuticals in a report on Tuesday, January 14th. Robert W. Baird decreased their price objective on shares of Apellis Pharmaceuticals from $92.00 to $55.00 and set an “outperform” rating on the stock in a research report on Thursday, November 7th. The Goldman Sachs Group downgraded shares of Apellis Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $36.00 price objective for the company. in a research note on Tuesday, December 17th. Morgan Stanley assumed coverage on Apellis Pharmaceuticals in a research note on Thursday, November 21st. They issued an “equal weight” rating and a $31.00 target price on the stock. Finally, Royal Bank of Canada reiterated a “sector perform” rating and issued a $26.00 price objective on shares of Apellis Pharmaceuticals in a report on Tuesday. Eight equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Apellis Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $46.71.

Hedge Funds Weigh In On Apellis Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the stock. Amalgamated Bank boosted its stake in Apellis Pharmaceuticals by 5.4% in the 2nd quarter. Amalgamated Bank now owns 6,995 shares of the company’s stock worth $268,000 after purchasing an additional 359 shares in the last quarter. KBC Group NV lifted its stake in shares of Apellis Pharmaceuticals by 34.8% in the third quarter. KBC Group NV now owns 2,632 shares of the company’s stock worth $76,000 after buying an additional 679 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Apellis Pharmaceuticals by 21.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,404 shares of the company’s stock valued at $130,000 after buying an additional 781 shares during the last quarter. Wolverine Asset Management LLC bought a new stake in shares of Apellis Pharmaceuticals during the third quarter valued at approximately $27,000. Finally, True Wealth Design LLC purchased a new position in Apellis Pharmaceuticals in the 3rd quarter worth approximately $27,000. 96.29% of the stock is currently owned by institutional investors.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).